Guest guest Posted March 18, 2011 Report Share Posted March 18, 2011 Interim Results From a Phase 1 Study of CAL-101, a Selective Oral Inhibitor of PI3K in Patients with Relapsed or Refractory Hematologic Malignancies N =106, (99 evaluable) relapsed/refractory, mixed histologies (CLL, indolent NHL, Aggressive NHL, AML, MM) PI3Ks are a family of lipid kinases that upon activation from extracellular signals, . leading to signaling cascades that can impact cancer cell growth, survival, motility and metabolism. In addition, CAL-101 inhibited the signaling of several receptors that interact with pro-survival factors from the tumor microenvironment, e.g., B-cell receptor, CXCR4, CD40 and BAFF receptor. CAL-101 treatment is generally well tolerated with minimal hematological toxicity. Reversible increase in ALT/AST is the most frequent adverse event. Slides ASCO 2010 http://bit.ly/hqMLvL Patients Against Lymphoma www.Lymphomation.org Evidence-based information on lymphoma, independent of health industry funding Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.